Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends in autoimmune rheumatic disease diagnoses before and after the COVID-19 pandemic in England: a population-based cohort study using OpenSAFELY.

The Lancet. Rheumatology·2026
Same author

Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144.

bioRxiv : the preprint server for biology·2026
Same author

Facial iPPG heatmap patterns based on period-aware autoencoder show association with carotid atherosclerosis towards non-contact hemodynamic assessment.

Computer methods and programs in biomedicine·2026
Same author

Quantification of Binding of Small Molecules to Native Kinases by Flow Cytometry Reveals Divergence from Biochemical Affinities.

Journal of the American Chemical Society·2026
Same author

Generation of high-expressing transposon-based stable pools to produce (1 + 1) and (2 + 1) bispecific common light chain antibodies.

Biotechnology progress·2026
Same author

Service Use and Engagement in Youth Mental Healthcare: National Trends in Jigsaw (2017-2022).

Early intervention in psychiatry·2026
Same journal

A Novel Anti-Glypican-3 Monoclonal Antibody G<sub>3</sub>Mab-25 for Versatile Applications.

Monoclonal antibodies in immunodiagnosis and immunotherapy·2026
Same journal

Epitope Mapping of Anti-mouse ACKR4 Monoclonal Antibodies Developed by N-Terminal Peptide Immunization.

Monoclonal antibodies in immunodiagnosis and immunotherapy·2026
Same journal

Epitope Mapping of Anti-Mouse C-C Motif Chemokine Receptor 1 Monoclonal Antibodies Developed by the Cell-Based Immunization and Screening Method.

Monoclonal antibodies in immunodiagnosis and immunotherapy·2026
Same journal

Guidelines for Reporting New Monoclonal Antibodies: Improving Transparency, Reproducibility, and Research Utility.

Monoclonal antibodies in immunodiagnosis and immunotherapy·2026
Same journal

Establishment of a Novel Anti-EphA4 Monoclonal Antibody, Ea<sub>4</sub>Mab-3, for Versatile Applications.

Monoclonal antibodies in immunodiagnosis and immunotherapy·2026
Same journal

Acknowledgment of Reviewers 2025.

Monoclonal antibodies in immunodiagnosis and immunotherapy·2026
See all related articles

Related Experiment Video

Updated: Jun 20, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.4K

Recombinant Antibody-Producing Stable CHOK1 Pool Stability Study.

Bailin Tu1, Zhihong Lin1, Jeff Moore1

  • 1Biologics Discovery and Design, Abbott Diagnostics Division, Abbott Laboratories, Abbott Park, Illinois, USA.

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy
|July 22, 2024
PubMed
Summary
This summary is machine-generated.

Developing stable mammalian cell lines for biologics manufacturing is crucial. The Leap-In transposase system offers a faster, semi site-specific integration method for generating high-yield, stable Chinese hamster ovary (CHO) cell pools for in vitro diagnostics (IVD) production.

Keywords:
antibody manufacturingcell culturein vitro diagnosticsrecombinationtransposase

More Related Videos

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.2K
Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells
08:15

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Published on: September 28, 2018

11.0K

Related Experiment Videos

Last Updated: Jun 20, 2025

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.4K
A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics
07:48

A High-throughput Automated Platform for the Development of Manufacturing Cell Lines for Protein Therapeutics

Published on: September 22, 2011

22.2K
Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells
08:15

Use of High-Throughput Automated Microbioreactor System for Production of Model IgG1 in CHO Cells

Published on: September 28, 2018

11.0K

Area of Science:

  • Biotechnology
  • Cell Line Development
  • Molecular Biology

Background:

  • Mammalian cell line stability is critical for biopharmaceutical and in vitro diagnostics (IVD) manufacturing.
  • Traditional random integration methods for cell line development are time-consuming and can lead to genetic instability.
  • New technologies aim to mitigate risks associated with genetic instability in cell line development.

Purpose of the Study:

  • To evaluate the Leap-In transposase-mediated expression system for generating stable Chinese hamster ovary (CHO) K1 cell pools.
  • To assess the productivity and stability of CHO K1 pools for producing recombinant antibody reagents for IVD immunoassays.
  • To compare the efficiency of site-specific integration with traditional random integration methods.

Main Methods:

  • Application of the ATUM Leap-In transposase system for semi site-specific integration in CHO K1 cells.
  • Generation of stable CHO K1 cell pools for the production of four recombinant antibody reagents.
  • Evaluation of cell line stability through consistent antibody production over time.
  • Assessment of the impact of L-glutamine on cell line stability and antibody titer.

Main Results:

  • Three out of four generated CHO K1 pools maintained stable productivity suitable for manufacturing, exhibiting high antibody yields.
  • One CHO K1 pool showed decreased productivity over time, but derivative clones demonstrated acceptable stability.
  • L-glutamine exhibited variable effects on cell line/pool stability and significantly impacted antibody product titer.

Conclusions:

  • The ATUM Leap-In transposase system facilitates the generation of high-yield, stable CHO cell pools for IVD manufacturing.
  • Semi site-specific integration using the Leap-In system reduces development time compared to traditional random integration methods.
  • The developed stable pools meet manufacturing stability requirements for recombinant antibody production.